These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9179692)

  • 1. PCNA and p53 in urinary bladder cancer: correlation with histological findings and prognosis.
    Inagaki T; Ebisuno S; Uekado Y; Hirano A; Hiroi A; Shinka T; Ohkawa T
    Int J Urol; 1997 Mar; 4(2):172-7. PubMed ID: 9179692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
    Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferating cell nuclear antigen cyclin in human transitional cell carcinoma.
    Hattori K; Uchida K; Akaza H; Koiso K; Nemoto R; Harada M
    Br J Urol; 1995 Feb; 75(2):162-6. PubMed ID: 7850319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage.
    Skopelitou A; Hadjiyannakis M; Dimopoulos D; Kamina S; Krikoni O; Alexopoulou V; Rigas C; Agnantis NJ
    Eur Urol; 1997; 31(4):464-71. PubMed ID: 9187909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
    Ogura K; Fukuzawa S; Habuchi T; Ogawa O; Yoshida O
    Int J Urol; 1997 Nov; 4(6):561-6. PubMed ID: 9477184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
    Ogura K; Habuchi T; Yamada H; Ogawa O; Yoshida O
    Int J Urol; 1995 Nov; 2(5):302-8. PubMed ID: 8749948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and prognostic value of proliferating cell nuclear antigen in transitional cell carcinoma of the urinary bladder.
    Chen G; Lin MS; Li RC
    Urol Res; 1997; 25(1):25-30. PubMed ID: 9079742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of immunohistochemical markers (PCNA, Ki-67, 486p and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors.
    Vorreuther R; Hake R; Borchmann P; Lukowsky S; Thiele J; Engelmann U
    Urol Int; 1997; 59(2):88-94. PubMed ID: 9392055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder].
    Kuczyk MA; Serth J; Bokemeyer C; Hervatin C; Oelke M; Oelert F; Höfner K; Jonas U
    Urologe A; 1995 Mar; 34(2):146-52. PubMed ID: 7754587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
    J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy?
    Steiner G; Bierhoff E; Schmidt D; Leissner J; Wolf HK; Albers P
    Eur J Cancer; 2000 Mar; 36(5):610-4. PubMed ID: 10738125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical studies of proliferating cell nuclear antigen and cathepsin D in transitional cell carcinoma of the urinary bladder.
    Iizumi T; Iiyama T; Tanaka W; Okada E; Kamiyama Y; Okano Y; Sato S; Yazaki T; Umeda T; Imamura T
    Urol Int; 1997; 59(2):81-7. PubMed ID: 9392054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus Calmette-Guerin (BCG) intravesical instillation therapy for superficial bladder cancers.
    Okamura T; Akita H; Kawai N; Tozawa K; Yamada Y; Kohri K
    Urol Res; 1998; 26(3):161-4. PubMed ID: 9694596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of P21, p53 and proliferating cell nuclear antigen in human bladder cancer].
    Ding Q; Zhang Y; Sun X
    Zhonghua Bing Li Xue Za Zhi; 1997 Aug; 26(4):211-3. PubMed ID: 10072865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
    Frank I; Cheville JC; Blute ML; Lohse CM; Karnes RJ; Weaver AL; Sebo TJ; Nehra A; Zincke H
    Cancer; 2004 Oct; 101(8):1803-8. PubMed ID: 15386300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of proliferating cell nuclear antigen expression in transitional cell carcinoma of the upper urinary tract.
    Cheng HL; Chow NH; Tzai TS; Tong YC; Lin JS; Chan SH; Yang WH; Chang CC; Lin YM
    Anticancer Res; 1997; 17(4A):2789-93. PubMed ID: 9252716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens.
    Tsuji M; Kojima K; Murakami Y; Kanayama H; Kagawa S
    Br J Urol; 1997 Mar; 79(3):367-72. PubMed ID: 9117215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.